The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Why do patients with multiple myeloma (MM) reaching measurable residual disease (MRD)-negativity still relapse?1 Could it be due to undetectable MRD inside or outside the bone marrow (BM) or because of so-called cancer stem cells (immature plasma cells [PCs])? Some patients with negative MRD by next generation flow (NGF) are positive by next generation sequencing NGS; NGF focuses on PCs whereas NGS evaluates all B cells and PCs. It is unknown whether immature cells have the same genetic background as MM PCs, so could it be that in some patients clonotypic cells are more immature than PCs?
In order to answer these questions, at the 61st American Society of Hematology Annual Meeting & Exposition, Orlando, FL, US, Sara Rodríguez, Centro de Investigación Médica Aplicada, University of Navarra, Pamplona, ES, reported the results of a study comparing the biological landscape of MM PCs at diagnosis to that of CD34+ progenitors, B cells and normal PCs isolated from patients with undetectable MRD by NGF after treatment.2
Clonal immunoglobulin (Ig) rearrangement
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content